The A736V TMPRSS6 Polymorphism Influences Hepatic Iron Overload in Nonalcoholic Fatty Liver Disease

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Valenti, Luca ^a   Rametta, Raffaela ^a   Dongiovanni, Paola ^a   Motta, Benedetta M ^a   Canavesi, Elena ^a   Pelusi, Serena ^a   Pulixi, Edoardo A ^a   Fracanzani, Anna L ^a   Fargion, Silvia ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEPCIDIN; TRANSFERRIN;

ADULT; AGE; ARTICLE; BETA THALASSEMIA; CONTROLLED STUDY; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HFE GENE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; SEX DIFFERENCE; TRANSMEMBRANE PROTEASE SERINE 6 GENE;

AMINO ACID SUBSTITUTION; BODY MASS INDEX; DYSLIPIDEMIAS; FATTY LIVER; FERRITINS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; IRON OVERLOAD; MEMBRANE PROTEINS; POLYMORPHISM, GENETIC; RISK FACTORS; SERINE ENDOPEPTIDASES;

EID: 84868349912     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048804     Document Type: Article

References (52)

1. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, et al. (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50: 1844-1850.
2. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, et al. (2005) Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48: 634-642.
3. Day CP, (2006) From fat to inflammation. Gastroenterology 130: 207-210.
4. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, et al. (2010) Homozygosity for the PNPLA3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51: 1209-1217.
5. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, et al. (2002) Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123: 134-140.
6. Musso G, Gambino R, Cassader M, Pagano G, (2012) Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43: 617-649.
7. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, et al. (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40: 1387-1395.
8. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, et al. (2000) Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132: 112-117.
9. Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, et al. (2001) Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 96: 2448-2455.
10. Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, et al. (2004) Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39: 179-187.
11. Valenti L, Fracanzani AL, Bugianesi E, Dongiovanni P, Galmozzi E, et al. (2010) HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 138: 905-912.
12. Valenti L, Canavesi E, Galmozzi E, Dongiovanni P, Rametta R, et al. (2010) Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 53: 927-933.
13. Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, et al. (1999) Insulin resistance-associated hepatic iron overload. Gastroenterology 117: 1155-1163.
14. Nelson JE, Wilson L, Brunt EM, Yeh M, Kleiner DE, et al. (2009) Hepatic iron deposition in reticuloendothelial cells but not hepatocytes is associated with more severe NASH: results from the NASH clinical research network. 2009 International BioIron society meeting. pp. 185.
15. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L, (2011) Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target. J Hepatol 55: 920-932.
16. Valenti L, Dongiovanni P, Fracanzani AL, Santorelli G, Fatta E, et al. (2003) Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 35: 172-178.
17. Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, et al. (2007) Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 102: 1251-1258.
18. Valenti L, Dongiovanni P, Piperno A, Fracanzani AL, Maggioni M, et al. (2006) alpha1-Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage. Hepatology 44: 857-864.
19. Haap M, Machann J, von Friedeburg C, Schick F, Stefan N, et al. (2011) Insulin Sensitivity and Liver Fat: Role of Iron Load. J Clin Endocrinol Metab 96: 958-961.
20. Zheng X, Jiang T, Wu H, Zhu D, Wang L, et al. (2012) Hepatic iron stores are increased as assessed by magnetic resonance imaging in a Chinese population with altered glucose homeostasis. Am J Clin Nutr 94: 1012-1019.
21. Forouhi NG, Harding AH, Allison M, Sandhu MS, Welch A, et al. (2007) Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 50: 949-956.
22. Shi Z, Hu X, Yuan B, Pan X, Meyer HE, et al. (2006) Association between serum ferritin, hemoglobin, iron intake, and diabetes in adults in Jiangsu, China. Diabetes Care 29: 1878-1883.
23. Shah SV, Fonseca VA, (2011) Iron and diabetes revisited. Diabetes Care 34: 1676-1677.
24. Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, et al. (2011) Serum Hepcidin and Macrophage Iron Correlate With MCP-1 Release and Vascular Damage in Patients With Metabolic Syndrome Alterations. Arterioscler Thromb Vasc Biol 31: 683-690.
25. Sullivan JL, (2007) Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med (Maywood) 232: 1014-1020.
26. Saeed O, Otsuka F, Polavarapu R, Karmali V, Weiss D, et al. (2012) Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol 32: 299-307.
27. Valenti L, Swinkels DW, Burdick L, Dongiovanni P, Tjalsma H, et al. (2011) Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 21: 568-575.
28. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, et al. (2008) The risk of severe liver disease in NAFLD with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48: 792-798.
29. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, et al. (2012) Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 55: 77-85.
30. Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, et al. (2011) Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 53: 448-457.
31. Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, et al. (2009) Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 50: 351-357.
32. Pietrangelo A, (2007) Hemochromatosis: an endocrine liver disease. Hepatology 46: 1291-1301.
33. Martinelli N, Traglia M, Campostrini N, Biino G, Corbella M, et al. (2012) Serum hepcidin levels in subjects with the metabolic syndrome. A population study. PLOS ONE in press.
34. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, et al. (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093.
35. Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, et al. (2008) Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 87: 1374-1383.
36. Ramsay AJ, Hooper JD, Folgueras AR, Velasco G, Lopez-Otin C, (2009) Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis. Haematologica 94: 840-849.
37. Finberg KE, (2009) Iron-refractory iron deficiency anemia. Semin Hematol 46: 378-386.
38. Nai A, Pagani A, Silvestri L, Campostrini N, Corbella M, et al. (2011) TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals. Blood 118: 4459-4462.
39. Benyamin B, Ferreira MA, Willemsen G, Gordon S, Middelberg RP, et al. (2009) Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet 41: 1173-1175.
40. Chambers JC, Zhang W, Li Y, Sehmi J, Wass MN, et al. (2009) Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet 41: 1170-1172.
41. Traglia M, Girelli D, Biino G, Campostrini N, Corbella M, et al. (2011) Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. J Med Genet 48: 629-634.
42. Tanaka T, Roy CN, Yao W, Matteini A, Semba RD, et al. (2010) A genome-wide association analysis of serum iron concentrations. Blood 115: 94-96.
43. Valenti L, Fracanzani A, Rametta R, Fraquelli M, Soverini G, et al. (2012) Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. J Hepatol in press.
44. Swinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, et al. (2008) Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS ONE 3: e2706.
45. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
46. Deugnier YM, Loreal O, Turlin B, Guyader D, Jouanolle H, et al. (1992) Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology 102: 2050-2059.
47. Tanaka T, Roy CN, Yao W, Matteini A, Semba RD, et al. (2009) A genome-wide association analysis of serum iron concentrations. Blood.
48. Delbini P, Vaja V, Graziadei G, Duca L, Nava I, et al. (2010) Genetic variability of TMPRSS6 and its association with iron deficiency anaemia. Br J Haematol 151: 281-Äì284.
49. Valenti L, Dongiovanni P, Fargion S, (2012) Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World J Gastroenterol 18: 3782-3786.
50. Finberg KE, Whittlesey RL, Andrews NC, (2011) Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice. Blood 117: 4590-4599.
51. Nai A, Pagani A, Mandelli G, Lidonnici MR, Silvestri L, et al. (2012) Deletion of Tmprss6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood 119: 5021-5029.
52. Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, et al. (2008) Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 48: 821-828.